Farnesyl acetate is an acyclic sesquiterpene ester used more often in fragrance chemistry and plant volatile profiling than in standalone aromatherapy literature. The current live evidence base is mixed but usable: reference sources support identity, a modern RIFM paper confirms that it has been reviewed as a fragrance ingredient, older cell work reported DNA-replication inhibition in cultured mammalian cells, and newer insect studies describe bioactivity against diamondback moth larvae. Those findings do not justify consumer medical copy, so AromaForge should present farnesyl acetate mainly as a fragrance-and-occurrence constituent with limited preclinical bioactivity and conservative safety framing.
Chemical identity and composition
PubChem lists farnesyl acetate as CID 94403 with formula C17H28O2 and the common IUPAC form 3,7,11-trimethyldodeca-2,6,10-trienyl acetate. Synonym data also include the farnesol acetate naming variant and the INCI-style fragrance identity. Structurally it is the acetate ester of farnesol, so it sits closer to long-chain floral sesquiterpene esters than to compact cyclic terpene markers.
Aroma and practical use
- Use the recorded oily, waxy, floral, green descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 1995 Experimental Cell Research paper reported that farnesyl acetate inhibited DNA replication in Chinese hamster ovary and HeLa cells, blocked progression through S phase, and also reduced protein prenylation in cells.
A 1995 Experimental Cell Research paper reported that farnesyl acetate inhibited DNA replication in Chinese hamster ovary and HeLa cells, blocked progression through S phase, and also reduced protein prenylation in cells.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2021 Insects study found that farnesyl acetate showed the strongest toxicity among the tested farnesyl derivatives against second-instar Plutella xylostella larvae, with an LC50 of 56.41 mg/L and clear sublethal effects on pupation, emergence, fecundity, and morphology.
A 2021 Insects study found that farnesyl acetate showed the strongest toxicity among the tested farnesyl derivatives against second-instar Plutella xylostella larvae, with an LC50 of 56.41 mg/L and clear sublethal effects on pupation, emergence, fecundity, and morphology.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2022 RIFM safety assessment established that farnesyl acetate has a dedicated modern fragrance-safety review record, which is more useful for exposure framing than for benefit claims.
A 2022 RIFM safety assessment established that farnesyl acetate has a dedicated modern fragrance-safety review record, which is more useful for exposure framing than for benefit claims.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
A modern RIFM fragrance ingredient safety assessment exists for farnesyl acetate, supporting conservative use of fragrance-safety literature rather than implying unreviewed consumer safety.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
The main direct bioactivity papers found for isolated farnesyl acetate involve cultured mammalian cells and pest insects, not human therapeutic studies.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
A constituent-specific public dermal sensitization threshold or inhalation exposure limit for isolated farnesyl acetate was not verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
irreversible_s_phase_block_in_cultured_cells
The main direct mechanism signal located is inhibition of DNA replication with irreversible S-phase blockade in hamster and HeLa cells reported in the 1995 cell study.
This experimental finding does not establish benefit, dose or safety in people using this blend.
insect_development_disruption
In diamondback moth larvae, sublethal farnesyl acetate exposure delayed development and increased abnormal pupal or adult forms, consistent with insect growth-disrupting activity.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical trial focused on isolated farnesyl acetate was verified in this pass.
- The most direct bioactivity literature is either old cell work or nonhuman insect research, which limits translational interpretation.
- No IFRA Standard exists for farnesyl acetate (unlike its parent alcohol farnesol) despite a 2022 RIFM safety assessment, so no category-specific dermal maximum could be sourced; the existing sensitizing:true flag on this record was not independently corroborated by a primary source in this pass and should be treated as unverified.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.